skip to main content

Welcome to Evgen Pharma PLC

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology. We are also researching a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.

Evgen Pharma Image Strategy

About

Evgen Pharma has a clear strategy for driving shareholder value from its technology

Read more

Evgen Pharma Image History

Management

Evgen Pharma has attracted a highly experienced commercial, scientific and advisory team

Read more

Evgen Pharma Image Organisation

History

Founded in 2007, Evgen Pharma has evolved quickly into a clinical stage company

Read more

Investors

Evgen Pharma is a publicly quoted company. Its shares trade under the ticker symbol EVG.

Find out more

Pipeline

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01, a synthetic, stabilised form of sulforaphane, is made using our proprietary Sulforadex® technology. We are also researching a number of analogues of the naturally occurring compound sulforaphane.

METASTATIC BREAST CANCER

Breast cancer is the largest cause of cancer deaths in women worldwide. In around 75% of breast cancers, the hormone oestrogen plays a key part in tumour growth

Read more

GLIOMA AND GLIOBLASTOMA

Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour

Read more

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2)

In-vitro and in-vivo data demonstrates that SFX-01 modifies SHP2, inhibiting its phosphatase activity; this phosphatase is implicated in many aspects of cancer.

Read more

Technology

The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.

Find out more